Asia-Pacific biopharma conferences in early 2025 are forging strategic partnerships, launching research initiatives, and accelerating drug development.
Asia-Pacific biopharma conferences in early 2025 are forging strategic partnerships, launching research initiatives, and accelerating drug development.
Landmark clinical results suggest preventative therapy could delay or halt Alzheimer’s onset in high-risk individuals, reshaping the outlook …
An established diagnostics firm gains critical funding to advance its wearable glucose monitoring technology and drive a strategic …
Innovation, investment, and ideals intersected dramatically at the AI Action Summit—held 10–11 February at Paris’s Grand Palais. Co-chaired …
The FDA has approved SPN-830 (Onapgo)—a novel subcutaneous apomorphine infusion device—offering continuous, effective management of motor fluctuations in …
Sarepta Therapeutics reports encouraging Phase III trial data for Elevidys, its AAV-based gene therapy for Duchenne muscular dystrophy, …
Daiichi Sankyo’s antibody–drug conjugate Datopotamab Deruxtecan secures U.S. approval, offering a new treatment for patients with previously treated …
Stablepharma moves toward first-in-human testing of SPVX02, a thermally stable tetanus–diphtheria booster that could revolutionise vaccine storage and …
A novel collaboration breaks ground with an inhaled mRNA therapy entering early clinical testing for the first time—a …
Generative AI has produced a novel TNIK-inhibiting compound now advancing in phase 2a trials—an unprecedented milestone in drug discovery.
Already a subscriber? Log in